Acute Coronary Syndrome

Millennium, partner begin trial with INTEGRILIN (eptifibatide) Injection

Published in Drug Week, July 2nd, 2004

Millennium Pharmaceuticals, Inc., (MLNM) and Schering-Plough Corp. (SGP) announced the initiation of a multicenter, phase IIIb, clinical trial to evaluate the benefit of INTEGRILIN when administered early to high-risk patients experiencing non-ST-segment elevation acute coronary syndrome.

The trial, known as EARLY ACS (early glycoprotein IIb-IIIa inhibition in non-st-segment elevation acute coronary syndrome: a randomized, placebo-controlled trial evaluating the clinical benefits of early front-loaded eptifibatide in the treatment of patients with non-st-segment elevation acute coronary syndrome) will evaluate the benefit of INTEGRILIN compared to placebo in reducing...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Drug Week

Source: Drug Week (2004-07-02)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry